medigraphic.com
ISSN 2500-7106 (Electronic)
ISSN 0123-2576 (Print)
Medicina & Laboratorio

2021, Number 2

<< Back Next >>

Medicina & Laboratorio 2021; 25 (2)

Kaposi sarcoma in lymph nodes after kidney transplantation: report of two cases in a Colombian transplant center

Palacios-Ramírez DA, Varela-Aguirre GJ

Language: Spanish
References: 34
Page: 525-534
PDF size: 896.19 Kb.


ABSTRACT

Cancer is a major cause of morbidity and mortality in transplant recipients. The combination of viral infections, immunosuppression therapy and immune system dysfunction in transplant patients contribute to the development of cancer. Kaposi sarcoma is caused by human herpes virus 8 (HHV-8) and although rare in the general population, it is reported to be up to 300 times more common in kidney transplant patients. Diagnosis of the disease is often made on the basis of the characteristic appearance of lesions, but must be confirmed by histology. In recent years, mTOR inhibitors have been shown to be effective in controlling Kaposi sarcoma in transplant patients, due to disruption of the antiapoptotic effect and angiogenesis dependent on the mTOR protein, which are essential for development and propagation of malignant cells. We present two case reports of patients with Kaposi sarcoma in lymph nodes and no skin lesions, who responded well to the immunosuppressive therapy switch with mTOR inhibitors.


REFERENCES

  1. Au E, Wong G, Chapman JR. Cancer in kidneytransplant recipients. Nat Rev Nephrol 2018;14:508-520. https://doi.org/10.1038/s41581-018-0022-6.

  2. Cheung CY, Tang SCW. An update on cancerafter kidney transplantation. Nephrol Dial Transplant2019;34:914-920. https://doi.org/10.1093/ndt/gfy262.

  3. Campistol JM, Eris J, Oberbauer R, Friend P,Hutchison B, Morales JM, et al. Sirolimus therapyafter early cyclosporine withdrawal reducesthe risk for cancer in adult renal transplantation.J Am Soc Nephrol 2006;17:581-589.https://doi.org/10.1681/asn.2005090993.

  4. Gutiérrez-Dalmau A, Revuelta I, CampistolJM. Renal transplantation and cancer: Focus onimmunosuppressive therapy. Trends in Transplant2007;1:3-14.

  5. Campistol JM, Cuervas-Mons V, Manito N,Almenar L, Arias M, Casafont F, et al. Newconcepts and best practices for managementof pre- and post-transplantation cancer. TransplantRev (Orlando) 2012;26:261-279. https://doi.org/10.1016/j.trre.2012.07.001.

  6. Siegel R, Naishadham D, Jemal A. Cancer statistics,2012. CA Cancer J Clin 2012;62:10-29.https://doi.org/10.3322/caac.20138.

  7. Webster A, Wong G, McDonald S. Australia andNew Zealand dialysis and transplant registry. The32th annual report. Chapter 10, Cancer report.Adelaide, South Australia: South Australian Healthand Medical Research Institute (SAHMRI); 2009.Acceso 05 de noviembre de 2020. Disponible enhttp://www.anzdata.org.au/.

  8. Cesarman E, Damania B, Krown SE, Martin J,Bower M, Whitby D. Kaposi sarcoma. Nat RevDis Primers 2019;5:9. https://doi.org/10.1038/s41572-019-0060-9.

  9. Bishop BN, Lynch DT. Kaposi sarcoma. TreasureIsland (FL): StatPearls Publishing; 2021. Acceso14 de noviembre de 2020. Disponible en https://www.ncbi.nlm.nih.gov/books/NBK534839/.

  10. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C.Cancer after kidney transplantation in the UnitedStates. Am J Transplant 2004;4:905-913. https://doi.org/10.1111/j.1600-6143.2004.00450.x.

  11. Plancoulaine S, Gessain A. [Epidemiologicalaspects of human herpesvirus 8 infectionand of Kaposi's sarcoma]. Med Mal Infect2005;35:314-321. https://doi.org/10.1016/j.medmal.2005.02.009.

  12. Volberding PA. 400 - Hematology and oncologyin patients with human immunodeficiencyvirus infection. In: Goldman L, Schafer AI, eds.Goldman's Cecil Medicine (Twenty Fourth Edition).Philadelphia: W.B. Saunders; 2012. p.2212-2217.

  13. Gutiérrez-Dalmau A, Campistol JM. Kaposi'ssarcoma after renal transplantation. N Engl JMed 2005;353:846-847.

  14. Schulte B, Linke D, Klumpp S, Schaller M,Riess T, Autenrieth IB, et al. Bartonella quintanavariably expressed outer membraneproteins mediate vascular endothelial growthfactor secretion but not host cell adherence.Infect Immun 2006;74:5003-5013. https://doi.org/10.1128/iai.00663-06.

  15. Piselli P, Taborelli M, Cimaglia C, Serraino D.Decreased incidence of Kaposi sarcoma afterkidney transplant in Italy and role of mTOR-inhibitors:1997-2016. Int J Cancer 2019;145:597-598. https://doi.org/10.1002/ijc.32098.

  16. Ahmadpoor P. Human herpesvirus-8 and Kaposisarcoma after kidney transplantation: mechanismsof tumor genesis. Iran J Kidney Dis2009;3:121-126.

  17. Kalt I, Masa SR, Sarid R. Linking the Kaposi'ssarcoma-associated herpesvirus (KSHV/HHV-8) to human malignancies. Methods Mol Biol2009;471:387-407. https://doi.org/10.1007/978-1-59745-416-2_19.

  18. Rewane A, Tadi P. Herpes virus type 8. TreasureIsland (FL): StatPearls Publishing; 2021. Acceso1 de noviembre de 2020. Disponible en https://www.ncbi.nlm.nih.gov/books/NBK556023/.

  19. Holdaas H, De Simone P, Zuckermann A.Everolimus and malignancy after solid organtransplantation: A clinical update. JTransplant 2016;2016:4369574. https://doi.org/10.1155/2016/4369574.

  20. Detroyer D, Deraedt K, Schöffski P, HaubenE, Lagrou K, Naesens M, et al. Resolution ofdiffuse skin and systemic Kaposi's sarcoma ina renal transplant recipient after introductionof everolimus: a case report. Transpl Infect Dis2015;17:303-307. https://doi.org/https://doi.org/10.1111/tid.12357.

  21. Einollahi B. Kaposi sarcoma after kidney transplantation.Iran J Kidney Dis 2007;1:2-11.

  22. Antman K, Chang Y. Kaposi's sarcoma. NEngl J Med 2000;342:1027-1038. https://doi.org/10.1056/nejm200004063421407.

  23. García PK, Córdoba Buritica JP, RodríguezMP, Echeverri JE, Lozano E, Benavides C. Sarcomade Kaposi en trasplante renal, respuestaa sirolimus: reporte de caso y revisión de la literaturacientífica. Univer Med 2010;52:209-218.

  24. Moray G, Başaran O, Yağmurdur MC,Emiroğlu R, Bilgin N, Haberal M. Immunosuppressivetherapy and Kaposi's sarcomaafter kidney transplantation. Transplant Proc2004;36:168-170. https://doi.org/10.1016/j.transproceed.2003.11.016.

  25. Penn I. Cancers in cyclosporine-treated vsazathioprine-treated patients. Transplant Proc1996;28:876-878.

  26. Fang Q, Wang X, Liu Z, Zhu M, Ding M, MinhasV, et al. Seroprevalence of human herpesvirus8 and its impact on the hemoglobinlevel in patients of end stage of renal diseases.J Med Virol 2018;90:338-343. https://doi.org/10.1002/jmv.24937.

  27. Francès C, Marcelin AG, Legendre C, ChevretS, Dussaix E, Lejeune J, et al. The impactof preexisting or acquired Kaposi sarcomaherpesvirus infection in kidney transplantrecipients on morbidity and survival. Am JTransplant 2009;9:2580-2586. https://doi.org/10.1111/j.1600-6143.2009.02816.x.

  28. Cahoon EK, Linet MS, Clarke CA, Pawlish KS,Engels EA, Pfeiffer RM. Risk of Kaposi sarcomaafter solid organ transplantation in the UnitedStates. Int J Cancer 2018;143:2741-2748.https://doi.org/10.1002/ijc.31735.

  29. Donia AF, Fouda MA, Ghoneim ME, RefaieAF, Ali-El-Dein B. The previously commonpost-kidney transplant Kaposi sarcoma hasbecome non-existent for a decade: an Egyptianexperience. J Cancer Res Clin Oncol 2020.https://doi.org/10.1007/s00432-020-03433-1.

  30. Campistol JM, Gutierrez-Dalmau A, TorregrosaJV. Conversion to sirolimus: asuccessful treatment for posttransplantationKaposi's sarcoma. Transplantation2004;77:760-762. https://doi.org/10.1097/01.tp.0000115344.18025.0b.

  31. Stallone G, Schena A, Infante B, Di PaoloS, Loverre A, Maggio G, et al. Sirolimus forKaposi's sarcoma in renal-transplant recipients.N Engl J Med 2005;352:1317-1323. https://doi.org/10.1056/NEJMoa042831.

  32. Wolf S, Hoffmann VS, Habicht A, Kauke T, BucherJ, Schoenberg M, et al. Effects of mTOR-Ison malignancy and survival following renal transplantation:A systematic review and meta-analysisof randomized trials with a minimum followupof 24 months. PLoS One 2018;13:e0194975.https://doi.org/10.1371/journal.pone.0194975.

  33. Abbaszadeh S, Taheri S. Kaposi's sarcomaafter renal transplantation. Saudi J Kidney DisTranspl 2009;20:775-778.

  34. Nauman A, Arshad A, Mujeeb I, Asim M. Renaltransplant failure due to infiltrating Kaposisarcoma. Exp Clin Transplant 2019;17:554-557.https://doi.org/10.6002/ect.2017.0052.




2020     |     www.medigraphic.com